185 related articles for article (PubMed ID: 36161671)
1. Management of Hypoparathyroidism.
Khan AA; Guyatt G; Ali DS; Bilezikian JP; Collins MT; Dandurand K; Mannstadt M; Murphy D; M'Hiri I; Rubin MR; Sanders R; Shrayyef M; Siggelkow H; Tabacco G; Tay YD; Van Uum S; Vokes T; Winer KK; Yao L; Rejnmark L
J Bone Miner Res; 2022 Dec; 37(12):2663-2677. PubMed ID: 36161671
[TBL] [Abstract][Full Text] [Related]
2. Evaluation and Management of Hypoparathyroidism Summary Statement and Guidelines from the Second International Workshop.
Khan AA; Bilezikian JP; Brandi ML; Clarke BL; Gittoes NJ; Pasieka JL; Rejnmark L; Shoback DM; Potts JT; Guyatt GH; Mannstadt M
J Bone Miner Res; 2022 Dec; 37(12):2568-2585. PubMed ID: 36054621
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and Safety of Parathyroid Hormone Replacement With TransCon PTH in Hypoparathyroidism: 26-Week Results From the Phase 3 PaTHway Trial.
Khan AA; Rubin MR; Schwarz P; Vokes T; Shoback DM; Gagnon C; Palermo A; Marcocci C; Clarke BL; Abbott LG; Hofbauer LC; Kohlmeier L; Pihl S; An X; Eng WF; Smith AR; Ukena J; Sibley CT; Shu AD; Rejnmark L
J Bone Miner Res; 2023 Jan; 38(1):14-25. PubMed ID: 36271471
[TBL] [Abstract][Full Text] [Related]
4. Management of hypoparathyroidism: a Position Statement of the Expert Group of the Polish Society of Endocrinology.
Misiorowski W; Dedecjus M; Konstantynowicz J; Zygmunt A; Kos-Kudła B; Lewiński A; Ruchała M; Zgliczyński W
Endokrynol Pol; 2023; 74(5):447-467. PubMed ID: 37902011
[TBL] [Abstract][Full Text] [Related]
5. Safety and Efficacy of PTH 1-34 and 1-84 Therapy in Chronic Hypoparathyroidism: A Meta-Analysis of Prospective Trials.
Puliani G; Hasenmajer V; Simonelli I; Sada V; Pofi R; Minnetti M; Cozzolino A; Napoli N; Pasqualetti P; Gianfrilli D; Isidori AM
J Bone Miner Res; 2022 Jul; 37(7):1233-1250. PubMed ID: 35485213
[TBL] [Abstract][Full Text] [Related]
6. Safety and Efficacy of Oral Human Parathyroid Hormone (1-34) in Hypoparathyroidism: An Open-Label Study.
Ish-Shalom S; Caraco Y; Khazen NS; Gershinsky M; Szalat A; Schwartz P; Arbit E; Galitzer H; Tang JC; Burshtein G; Rothner A; Raskin A; Blum M; Fraser WD
J Bone Miner Res; 2021 Jun; 36(6):1060-1068. PubMed ID: 33666947
[TBL] [Abstract][Full Text] [Related]
7. The Clinical and Skeletal Effects of Long-Term Therapy of Hypoparathyroidism With rhPTH(1-84).
Agarwal S; McMahon DJ; Chen J; Brossfield AV; Fernando J; Bilezikian JP; Cusano NE; Rubin MR
J Bone Miner Res; 2023 Apr; 38(4):480-492. PubMed ID: 36726204
[TBL] [Abstract][Full Text] [Related]
8. PTH(1-84) replacement therapy in hypoparathyroidism: a randomized controlled trial on pharmacokinetic and dynamic effects after 6 months of treatment.
Sikjaer T; Amstrup AK; Rolighed L; Kjaer SG; Mosekilde L; Rejnmark L
J Bone Miner Res; 2013 Oct; 28(10):2232-43. PubMed ID: 23649554
[TBL] [Abstract][Full Text] [Related]
9. Parathyroid Hormone Therapy for Managing Chronic Hypoparathyroidism: A Systematic Review and Meta-Analysis.
Yao L; Li J; Li M; Lin C; Hui X; Tamilselvan D; Kandi M; Sreekanta A; Makhdami N; Ali DS; Dandurand K; Yang K; Bilezikian JP; Brandi ML; Clarke BL; Mannstadt M; Rejnmark L; Khan AA; Guyatt G
J Bone Miner Res; 2022 Dec; 37(12):2654-2662. PubMed ID: 36385517
[TBL] [Abstract][Full Text] [Related]
10. Etiology and Pathophysiology of Hypoparathyroidism: A Narrative Review.
Pasieka JL; Wentworth K; Yeo CT; Cremers S; Dempster D; Fukumoto S; Goswami R; Houillier P; Levine MA; Pasternak JD; Perrier ND; Sitges-Serra A; Shoback DM
J Bone Miner Res; 2022 Dec; 37(12):2586-2601. PubMed ID: 36153665
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics and pharmacodynamics of subcutaneous recombinant parathyroid hormone (1-84) in patients with hypoparathyroidism: an open-label, single-dose, phase I study.
Clarke BL; Kay Berg J; Fox J; Cyran JA; Lagast H
Clin Ther; 2014 May; 36(5):722-36. PubMed ID: 24802860
[TBL] [Abstract][Full Text] [Related]
12. Hypoparathyroidism.
Al-Azem H; Khan AA
Best Pract Res Clin Endocrinol Metab; 2012 Aug; 26(4):517-22. PubMed ID: 22863393
[TBL] [Abstract][Full Text] [Related]
13. The Efficacy and Safety of Medical and Surgical Therapy in Patients With Primary Hyperparathyroidism: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Ye Z; Silverberg SJ; Sreekanta A; Tong K; Wang Y; Chang Y; Zhang M; Guyatt G; Tangamornsuksun W; Zhang Y; Manja V; Bakaa L; Couban RJ; Brandi ML; Clarke B; Khan AA; Mannstadt M; Bilezikian JP
J Bone Miner Res; 2022 Nov; 37(11):2351-2372. PubMed ID: 36053960
[TBL] [Abstract][Full Text] [Related]
14. Parathyroid hormone therapy for hypoparathyroidism.
Cusano NE; Rubin MR; Bilezikian JP
Best Pract Res Clin Endocrinol Metab; 2015 Jan; 29(1):47-55. PubMed ID: 25617172
[TBL] [Abstract][Full Text] [Related]
15. Autosomal Dominant Hypocalcemia Type 1: A Systematic Review.
Roszko KL; Stapleton Smith LM; Sridhar AV; Roberts MS; Hartley IR; Gafni RI; Collins MT; Fox JC; Nemeth EF
J Bone Miner Res; 2022 Oct; 37(10):1926-1935. PubMed ID: 35879818
[TBL] [Abstract][Full Text] [Related]
16. Treatment of Hypoparathyroidism by Re-Establishing the Effects of Parathyroid Hormone.
Rejnmark L
Endocrinol Metab (Seoul); 2024 Apr; 39(2):262-266. PubMed ID: 38572533
[TBL] [Abstract][Full Text] [Related]
17. Initial Assessment and Monitoring of Patients with Chronic Hypoparathyroidism: A Systematic Current Practice Survey.
Van Uum S; Shrayyef M; M'Hiri I; Dandurand K; Ali DS; Bilezikian JP; Collins MT; Mannstadt M; Rubin MR; Siggelkow H; Tabacco G; Tay YD; Vokes T; Winer KK; Yao L; Guyatt G; Rejnmark L; Khan AA
J Bone Miner Res; 2022 Dec; 37(12):2630-2641. PubMed ID: 36066096
[TBL] [Abstract][Full Text] [Related]
18. Postoperative hypoparathyroidism: medical and surgical therapeutic options.
Walker Harris V; Jan De Beur S
Thyroid; 2009 Sep; 19(9):967-73. PubMed ID: 19731978
[TBL] [Abstract][Full Text] [Related]
19. Hypoparathyroidism: Genetics and Diagnosis.
Mannstadt M; Cianferotti L; Gafni RI; Giusti F; Kemp EH; Koch CA; Roszko KL; Yao L; Guyatt GH; Thakker RV; Xia W; Brandi ML
J Bone Miner Res; 2022 Dec; 37(12):2615-2629. PubMed ID: 36375809
[TBL] [Abstract][Full Text] [Related]
20. Therapy with PTH 1-34 or calcitriol and calcium in diverse etiologies of hypoparathyroidism over 27 years at a single tertiary care center.
Winer KK; Ye S; Ferré EMN; Schmitt MM; Zhang B; Cutler GB; Lionakis MS
Bone; 2021 Aug; 149():115977. PubMed ID: 33932619
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
